Thelansis

 Pouchitis, an inflammatory condition in the ileal pouch reservoir, is a common long-term complication in patients who've undergone IPAA surgery for ulcerative colitis. It significantly impacts their quality of life. Studies report a cumulative frequency of 23% to 46% over 10-11 years post-surgery. Approximately half of UC patients with IPAA surgery will experience pouchitis at least once. Pouchitis primarily occurs in patients with underlying UC and is rare in those with FAP. Its exact cause remains uncertain, but evidence suggests it results from an abnormal immune response to changes in pouch microflora, causing inflammation. Pouchitis and UC share similar tissue cytokine profiles but are distinct conditions. The role of T-cell-mediated intestinal immunity in pouchitis remains unclear, likely linked to pouch microflora alterations. Changes in macrophage and T cell subpopulations have been suggested in pouchitis development. ·        The frequency ...

 Pouchitis is defined as acute inflammation of the ileal pouch created in UC or FAP patients following a total proctocolectomy and IPAA. ·        Pouchitis differs depending on the underlying pathology for which surgery was performed. According to Thelansis disease modeling data, results of literature reviews, surveys, and registry analyses incidence of about 50% of patients with an ileal pouch for UC will develop at least one episode of pouchitis, while those with FAP have a much lower incidence of pouchitis (0-11%). Thelansis’s “Pouchitis Market Outlook, Epidemiology, Competitive Landscape , and Market Forecast Report – 2021 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Pouchitis treatment modalities options for eight major markets (USA, Germany,...